Paul Hastings

South San Francisco, California, United States
Mr. Hastings was appointed Chief Executive Officer of Nkarta in February 2018. Mr. Hastings was recently the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.

He is currently Lead Independent Director of Pacira Biosciences, Inc., and Director at ViaCyte. He also serves as Chair of the Biotechnology Innovation Organization (BIO). Mr. Hastings was recently the Chairman of the Board of Proteon Therapeutics, was on the Board of Directors of Relypsa, Inc. (acquired by Galenica), was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010) and served on the board of ViaCell (sold to Perkin-Elmer in 2007).

Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
Speaking In
1:00 PM - 2:00 PM (PDT)
Monday, June 13
Jim Geraghty, a board director of five NASDAQ-listed biotech companies and author, joins a…
9:00 AM - 9:10 AM (PDT)
Wednesday, June 15
Opening remarks made by BIO's Chair, CEO of Nkarta Therapeutics, Paul Hastings.
1:45 PM - 2:45 PM (PDT)
Wednesday, June 15
Executives can ignite change in the biotechnology ecosystem through strategic funding and company…